- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04840056
Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis (GIMA)
Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis - Application of Artificial Intelligence in Histology and Clinical Data
The primary objectives of this study are:
- To identify clinical or histological factors associated with gastric cancer development in patients with IM and AG
- To establish a machine learning algorithm for prediction of future gastric cancer risks and individual risk stratification in patient with IM and AG
Study Overview
Status
Detailed Description
This is a two-part retrospective study including a clinical data part and a pathology part. A training cohort will be developed from approximately 70% of included cases. It will be followed by a validation cohort with the remaining cases.
Clinical data will be collected retrospectively using the Clinical Data Analysis and Reporting System (CDARS) and Clinical management System (CMS). A cluster-wide cohort (New Territories East Cluster, NTEC) consisting of patients with history of histologically-proven gastric IM and AG will be identified and included for subsequent analysis. The data collection period for the retrospective data will be 2000-2020.
Histology slides will be retrieved retrospectively when available (within NTEC). Whole slide imaging technique will be utilized for the development of training and validation cohorts with machine learning algorithms in the pathology part.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Felix Sia
- Phone Number: +85226370428
- Email: felix.sia@cuhk.edu.hk
Study Contact Backup
- Name: Thomas Lam
- Phone Number: +85226370428
- Email: thomas.lam@cuhk.edu.hk
Study Locations
-
-
New Territories
-
Shatin, New Territories, Hong Kong
- Recruiting
- Prince of Wales Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Clinical data will be collected retrospectively using the Clinical Data Analysis and Reporting System (CDARS) and Clinical management System (CMS). A cluster-wide cohort (New Territories East Cluster, NTEC) consisting of patients with history of histologically-proven gastric IM and AG will be identified and included for subsequent analysis. The data collection period for the retrospective data will be 2000-2020.
Histology slides will be retrieved retrospectively when available (within NTEC). Whole slide imaging technique will be utilized for the development of training and validation cohorts with machine learning algorithms in the pathology part.
Description
Inclusion Criteria:
- Adults >= 18 years of age
- Histologically proven atrophic gastritis or intestinal metaplasia (at antrum and/or body and/or angular of stomach)
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Intestinal Metaplasia
patient with history of histologically proven gastric intestinal metaplasia
|
|
Atrophic gastritis
patient with history of histologically proven atrophic gastritis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gastric cancer and gastric dysplasia
Time Frame: 20 years
|
The primary endpoint is the incidence of gastric cancer (intestinal-type) and gastric dysplasia (low grade and high grade dysplasia).
|
20 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall accuracy of machine learning model
Time Frame: 20 years
|
Overall accuracy of machine learning models will be evaluated
|
20 years
|
|
Sensitivity of machine learning model
Time Frame: 20 years
|
Sensitivity of machine learning model will be evaluated
|
20 years
|
|
Specificity of machine learning model
Time Frame: 20 years
|
Specificity of machine learning model will be evaluated
|
20 years
|
|
Positive predictive value of machine learning model
Time Frame: 20 years
|
Positive predictive value of machine learning model will be evaluated
|
20 years
|
|
Negative predictive value of machine learning model
Time Frame: 20 years
|
Negative predictive value of machine learning model will be evaluated
|
20 years
|
|
Area under the receiver operating characteristic curve of machine learning model
Time Frame: 20 years
|
Area under the receiver operating characteristic curve of machine learning model will be evaluated
|
20 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021.082
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.